A Phase 3 interventional study of mibavademab in Generalized Lipodystrophy, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.
Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 123rd largest by enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 6 in phase 3, and was the 205th registered.
941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.
Browse Obesity, Morbid studies →28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
The Cleveland Clinic · Sites in United States
Ages 18–70
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Women only
University of Missouri-Columbia · Sites in United States
Ages 18+
Salvador Navarrete · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 110 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 84 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 8 · Phase 4 13
First in 1980; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 62 across 602 interventional studies indexed under Obesity, Morbid.
Median enrollment 39 across the 150 interventional studies, 50 across the 63 observational. Of the 147 that completed or were terminated, 56 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 213 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
8 of the studies in Obesity, Morbid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06199154University of Maryland, BaltimoreInduction of Labor in Morbidly Obese Patients | 2026-12 |
| NCT05711758Christopher C. Thompson, MD, MScEfficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure | 2026-12 |
| NCT02602769Columbia UniversityWhole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome | 2026-12 |
| NCT05215886University of California, DavisCognitive Impairment, Obesity, and the Effects of Bariatric Surgery | 2026-12-31 |
| NCT03868592Mayo ClinicLong-term, Substantial Weight Loss and Insulin Regulation of Lipolysis | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 213 studies in Obesity, Morbid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
The aim of the study is to see how safe and tolerable mibavademab is when switching from treatment with metreleptin.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion / exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients switching from at least 6 months of therapy with metreleptin to mibavademab.
Drug: mibavademab
Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
Also known as: REGN4461
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Up to week 68
Severity of TEAEs
Time frame: Up to week 68
Change in Hemoglobin A1c (HbA1c)
Time frame: Baseline, week 20 and week 52
Occurrence of HbA1c <7%
Time frame: Week 20 and week 52
Occurrence of HbA1c <6.5%
Time frame: Week 20 and week 52
Occurrence of requiring therapy with insulin in participants treated with mibavademab
Time frame: Week 20 and week 52
Change in total insulin dose
Time frame: Baseline, week 20 and week 52
Change in fasting plasma glucose
Time frame: Baseline, week 20 and week 52
Percent change in fasting triglycerides
Time frame: Baseline, week 20 and week 52
Occurrence of fasting triglycerides <500 mg/dL in participants treated with mibavademab
Time frame: Baseline, week 20 and week 52
Occurrence of fasting triglycerides <200 mg/dL in participants treated with mibavademab
Time frame: Baseline, week 20 and week 52
Occurrence of fasting triglycerides <150 mg/dL in participants treated with mibavademab
Time frame: Baseline, week 20 and week 52
Concentrations of total mibavademab in serum
Time frame: Up to week 68
Incidence of anti-drug antibodies (ADAs) to mibavademab
Time frame: Up to week 68
Titer of ADAs to mibavademab
Time frame: Up to week 68
Incidence of neutralizing antibodies (Nabs) to mibavademab
Time frame: Up to week 68
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has : received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Jul 2026, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mibavademab